Biocryst Pharmaceuticals (BCRX) Other Operating Expenses (2012 - 2026)

Biocryst Pharmaceuticals has reported Other Operating Expenses for 15 years, with the latest figure at $703.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 15292.69% year-over-year to $703.1 million; the trailing twelve-month figure through Mar 2026 stood at $717.6 million (up 4508.56% YoY), and the FY2025 full-year result was $19.1 million, up 55.47% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $703.1 million, up from $9.5 million in the prior quarter.
• The five-year high for Other Operating Expenses was $703.1 million in Q1 2026, with the low at $238000.0 in Q1 2022.
• Historically, Other Operating Expenses has averaged $43.9 million across 5 years, with a median of $2.2 million in 2025.
• Annual changes were most pronounced in 2022 — Other Operating Expenses sank 95.96% — and 2026, when it jumped 15292.69%.
• Biocryst Pharmaceuticals' Other Operating Expenses stood at $2.5 million in 2022, then sank by 41.63% to $1.5 million in 2023, then jumped by 318.26% to $6.1 million in 2024, then soared by 56.25% to $9.5 million in 2025, then soared by 7284.35% to $703.1 million in 2026.
• The last three Other Operating Expenses figures came in at $703.1 million (Q1 2026), $9.5 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.